In this episode of the Making Impact Series, Helen is joined by Vangelis Vergetis, co-founder of Intelligencia. Vangelis has spent the last 15 years in healthcare, particularly on the interface between life sciences, technology, and data science. Prior to founding Intelligencia, Vangelis spent about a dozen years as a consultant at McKinsey and at Hakluyt, working with clients across different areas within healthcare. He is a board member and member of the executive committee at the Alliance for AI in Healthcare (AAIH), and a member of the advisory board for Cornell’s department of Computer & Information Science (CIS).

Intelligencia helps bring novel therapies to patients faster and more efficiently by applying Data Science to drug development. Based on a unique wealth of proprietary and expertly curated data, Intelligencia has been pioneering the use of Machine Learning algorithms to assess, quantify, and reduce the risk of clinical development.

0:59 - Vangelis’s background & origin story

3:24 - Focusing on risk & drug development

7:20 - The question of building the product vs buying the product

10:15 - The main value proposition and benefits for utilizing Intelligencia

13:12 - The ultimate impact that Intelligencia is having on patients & their journeys

15:49 - Where Intelligencia is as a startup

18:18 - What impact Vangelis is looking to make in the industry

Resources

Intelligencia: https://www.intelligencia.ai/

Connect With ODAIA

Blog: www.odaia.ai/making-impact/intelligencia-uses-artificial-intelligence-to-provide-data-clarity-for-pharma-bridging-the-gap-between-innovation-and-risk-reduction

Website: https://www.odaia.ai/

LinkedIn: https://www.linkedin.com/company/odaiaintelligence/

Contact Us: https://www.odaia.ai/contact